In lung cancer xenograft models, XPO1 inhibition interfered with NE transformation by downregulating SOX2, a key driver of NSCLC-to-SCLC lineage plasticity, thereby prolonging the efficacy of targeted therapies and supporting XPO1 inhibition as a strategy to constrain NE reprogramming [78]. The gene discussed is XPO1; the disease is small cell lung carcinoma.